COMEDK 2025 exam postponed in 12 cities due to Operation Sindoor: Revised dates to be announced soon
Comed-K Under graduate Entrance Test 2025, scheduled to be held on May 10, has been postponed in select cities in accordance with directives issued by the Indian government under Operation 'Sindoor'The affected test cities are Gujarat: Jamnagar (Test City Code: 26428); Jammu and Kashmir: Srinagar (14126), Jammu (7994); Punjab: Ludhiana (14458), Bathinda (1686), Jalandhar (2288), Mohali (38190), Patiala (8756), Amritsar (8799) and Rajasthan: Jodhpur (16596), Bikaner (8665), Sriganganagar (28906).Around 3000 students were expected to take exams in these centres.As per official instructions, educational institutions and establishments in these cities have been directed to close. The revised dates for these centres will be announced later, said a press release from Comed-K.'Candidates assigned to centers in these cities are advised not to panic. All candidates are requested to regularly check the official website www.comedk.org and www.unigauge.com for further updates and instructions,' the release read.'We have sent individual communication to all students regarding the postponement. We have advised them not to panic and will hold the exam on an alternate day whenever the government permits,' said Dr S Kumar, secretary, Comed-K.The examination will proceed as scheduled for all other candidates in other cities on May 10, 2025 at the time slots/session mentioned in their Test Admission Tickets.Around 1.31 lakh students are to appear for Comed-K's (Consortium of Medical, Dental and Engineering colleges of Karnataka) entrance on Saturday for engineering programmes in private colleges of Karnataka and select pan India member universities.While the practice was to hold the exam every second Sunday in May, it has been shifted to Saturday following clash with another exam.For any queries, candidates may reach out to the COMEDK helpdesk at:Tel: 080-46671060Email: studenthelpdesk@comedk.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
22 minutes ago
- News18
What Is Fentanyl? UPSC Aspirants Must Know As ‘US Works With India'. There's China Link Too
Last Updated: The FBI has been working with the Indian government to address the fentanyl crisis in the US. The US government has recently flagged the health crisis surrounding the illegal use of fentanyl, which has led to multiple cases of overdose and addiction. The number of fentanyl- and other opioid-related deaths has been on the rise since 1999, with distinct waves of increase in cases. However, what has driven the crisis? As per a new US intelligence report, India has emerged as a growing player in the illicit fentanyl trade. Fentanyl is a powerful synthetic opioid that can be more dangerous than morphine and is counted among the most common drugs involved in overdose deaths in the US. Creating a crisis in the country, fentanyl has become a top priority issue for the Trump administration. China has been the largest source of both legal supplies of the drug as well as illicit supplies of precursor chemicals, which are processed in Mexico before being smuggled to the US. According to a 2025 Annual Threat Assessment (ATA) report published by the Office of the Director of National Intelligence, 'Nonstate groups are often enabled, both directly and indirectly, by state actors, such as China and India, as sources of precursors and equipment for drug traffickers. China remains the primary source country for illicit fentanyl precursor chemicals and pill pressing equipment, followed by India." India And The US Working On the Fentanyl Crisis While the US government is trying to tackle the crisis, FBI director Kash Patel has recently opened up on how the Trump administration has been working with the Indian government to address the matter. During his recent appearance on The Joe Rogan Experience podcast, Patel explained how both countries have collaborated to dismantle the network, which uses India as a transit point for smuggling the chemical precursors from China to the Mexican drug cartels. 'They're going to places like India, and I'm also doing operations in India. You don't hear fentanyl deaths in India. You don't hear fentanyl deaths in England, Australia, New Zealand, or Five Eyes partners in Canada," he said while accusing the Chinese communist party of using fentanyl as a weapon against the US. Patel also went on to detail how the FBI has maintained direct communication with the Indian authorities to tackle the issue. 'I just got off the phone with the Indian government. We're going to find these companies that buy it, and we're going to shut them down," he continued. Fentanyl Topic For UPSC Students With the United States intensifying its fight to disrupt the global fentanyl network, it can be perceived as a major topic in the UPSC examinations under the segment of current affairs. What Is Fentanyl? Fentanyl is an opioid drug, just like morphine and heroin, made entirely in laboratories without any natural ingredients. Though it has been approved as a prescribed pain medicine, most of the fentanyl has contributed to the current overdose. Being more powerful than any other opioid, a small amount of fentanyl can cause a fatal overdose or changes in brain activity if used repeatedly. Speaking of its impact, a recent study found that the use of fentanyl has 'nearly quadrupled" among people between the ages of 15 and 24 from 2018 to 2022. First Published: June 11, 2025, 13:54 IST
Time of India
an hour ago
- Time of India
Dhyanguru Raghunath Guruji starts awareness campaign on domestic, chemical, medical waste segregation
On World Environment Day, spiritual leader and environmental activist Dhyanguru Raghunath Guruji launched a national awareness initiative focused on the segregation of household chemical and medical waste. The campaign, starting from Pune, aims to educate citizens across urban and rural areas about the hazards of improper waste disposal and the need for structured segregation at the source. Raghunath Guruji, who has blended spirituality with science, has been at the forefront of environmental activism since 2014. Known for integrating scientific thought into Indian cultural and spiritual practices, Guruji raised the issue of separating chemical and biomedical waste at a time when the focus was only on wet and dry waste. His efforts have since been adopted in various regions across India. According to government data, India generates over 700 tonnes of biomedical waste daily, with a significant portion originating from households. Similarly, around 7.9 million tonnes of hazardous chemical waste is produced annually. Household items such as expired medicines, used syringes, batteries, paints, body sprays, pesticides, shampoos, and cosmetics significantly contribute to this waste and have a serious impact on air, water, and soil. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free Chess. No Ads. Just Fun Play Classic Chess Install Now Undo Guruji emphasises that segregating medical and chemical waste at the household level is no longer optional—it is essential. Through his initiative, he encourages families to maintain separate dustbins: Yellow bins for medical waste Red bins for chemical waste Composting and recycling for organic and dry waste He has called upon citizens, NGOs, educational institutions, municipal bodies, political leaders, and industrial stakeholders to join hands in this critical mission. Weekly collection systems, proper incineration, and neutralisation or recycling of chemical waste are key components of the plan. 'Waste is not just a household problem—it's a public health and environmental emergency,' says Guruji. 'Protecting the environment means securing our future.' This month-long campaign will run in various parts of Pune and gradually expand across the country, with the goal of achieving a 'Waste-Free Environment' for India.
Time of India
an hour ago
- Time of India
AI, patents, and phygital models: A new direction in India's healthcare ecosystem
In a notable development for India's evolving healthcare supply chain, S&P Health has announced a strategic leadership expansion to support its AI-powered B2B & B2C healthcare platform. The move signals a stronger focus on integrating technology, regulatory insight, and diverse sectoral expertise to address persistent gaps in pharma retail and Patra, an IIM Kolkata alumnus with over two decades of leadership across pharmaceutical majors such as Emami, AstraZeneca, Zydus Cadila, and IPCA, continues to lead the platform's transformation. Patra holds three published patents that frame S&P Health's technological and operational core: • A direct-to-retail generics distribution model (Patent No. 201731047200) • A regulated digital marketplace for healthcare products (Patent No. 202031035561) • An AI-enabled B2B pharma e-commerce system (Patent No. 202431022304) These innovations aim to improve supply chain visibility, reduce inefficiencies in last-mile delivery, and modernize access to over-the-counter and chronic care medications across India's fragmented retail network. S&P Health operates through four integrated divisions: private label offerings, branded generics, manufacturer partnerships, and collaborative brand launches. Its technology-led infrastructure includes centralized warehousing, Just-In-Time inventory practices, and predictive logistics, underpinned by AI-driven insights. 'Our goal is to build a future-ready healthcare platform that is inclusive, efficient, and technology-driven,' said Sougata Patra. 'By combining regulatory foresight with AI and operational scale, we are working toward a more responsive pharma supply chain.' S&P Health's marketplace reportedly serves thousands of stockists and lakhs of retail chemists, addressing a wide spectrum of therapeutic areas including supplements, pain relief, sexual wellness, geriatric care, and chronic condition management. The company's technology stack also incorporates retailer enablement tools, allowing for real-time ordering, inventory forecasting, and compliance support. Expanding its leadership, the company has appointed entrepreneur Sunny Leone as Executive Director (N.E.) and investor, alongside Daniel Weber, who also joins the executive team. While best known for her global entertainment and entrepreneurial ventures, Leone's entry into the healthcare sector is positioned to bring an alternative lens to consumer engagement, especially in wellness, OTC, and preventive health categories. The leadership additions reflect a growing trend of cross-sectoral collaboration in Indian healthtech. India's B2B health distribution segment remains under-digitized compared to its consumer-facing counterparts. Platforms like S&P Health are emerging to fill critical infrastructure and technology gaps—especially in underserved markets—by combining physical distribution with data-driven operations in what the company calls a 'phy-gital' model. As regulatory compliance, pricing transparency, and supply chain efficiency continue to define the future of Indian pharma, S&P Health's next phase will be closely watched for its ability to scale its patented models and sustain platform-driven engagement across regions.
